Platelet hyperfunction is decreased by additional aspirin loading in patients presenting with myocardial infarction on daily aspirin therapy

Critical Care Medicine

Volumn 38, Issue 6, 2010, Pages 1423-1429

  Fuchs, Ingrid ^a   Spiel, Alexander O ^a   Frossard, Martin ^a   Derhaschnig, Ulla ^a   Riedmüller, Eva ^a   Jilma, Bernd ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Acute coronary syndrome; Aspirin; Platelet reactivity; Randomized controlled trial

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; PLACEBO; THROMBOXANE B2;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EMERGENCY WARD; FEMALE; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE FUNCTION; THROMBOCYTE HYPERFUNCTION; THROMBOCYTOPATHY;

EID: 77953083154     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181de8b1e     Document Type: Article

References (41)

1. Topalian S, Ginsberg F, Parrillo JE: Cardiogenic shock. Crit Care Med 2008; 36:S66-74
2. Wilansky S, Moreno CA, Lester SJ: Complications of myocardial infarction. Crit Care Med 2007; 35:S348-S354
3. Marenzi G, Assanelli E, Campodonico J, et al: Acute kidney injury in ST-segment elevation acute myocardial infarction complicated by cardiogenic shock at admission. Crit Care Med 2010; 38:434-444
4. Russ MA, Prondzinsky R, Carter JM, et al: Right ventricular function in myocardial infarction complicated by cardiogenic shock: Improvement with levosimendan. Crit Care Med 2009; 37:3017-3023
5. Katz JN, Shah BR, Volz EM, et al: Evolution of the coronary care unit: Clinical characteristics and temporal trends in healthcare delivery and outcomes. Crit Care Med 2010; 38:375-381
6. Hamon M, Agostini D, Le Page O, et al: Prognostic impact of right ventricular involvement in patients with acute myocardial infarction: Meta-analysis. Crit Care Med 2008; 36:2023-2033
7. Reynolds RM, Walker BR, Haw S, et al: Low serum cortisol predicts early death after acute myocardial infarction. Crit Care Med 2010; 38:973-975
8. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2:349-360
9. Winning J, Neumann J, Kohl M, et al: Antiplatelet drugs and outcome in mixed admissions to an intensive care unit. Crit Care Med 2010; 38:32-37
10. Bassand JP, Hamm CW, Ardissino D, et al: Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007; 28:1598-1660
11. Antman EM, Hand M, Armstrong PW, et al: 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2008; 51:210-247
12. Anderson JL, Adams CD, Antman EM, et al: ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007; 50:e1-e157
13. Quinn MJ, Aronow HD, Califf RM, et al: Aspirin dose and six-month outcome after an acute coronary syndrome. J Am Coll Cardiol 2004; 43:972-978
14. Aronow HD, Califf RM, Harrington RA, et al: Relation between aspirin dose, all-cause mortality, and bleeding in patients with recent cerebrovascular or coronary ischemic events (from the BRAVO Trial). Am J Cardiol 2008; 102:1285-1290
15. Zimmermann N, Hohlfeld T: Clinical implications of aspirin resistance. Thromb Haemost 2008; 100:379-390
16. Homoncik M, Jilma B, Hergovich N, et al: Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. Thromb Haemost 2000; 83:316-321
17. Derhaschnig U, Pachinger C, Jilma B: Variable inhibition of high-shear-induced platelet plug formation by eptifibatide and tirofiban under conditions of platelet activation and high von Willebrand release: A randomized, placebo-controlled, clinical trial. Am Heart J 2004; 147:E17
18. Alpert JS, Thygesen K, Antman E, et al: Myocardial infarction redefined - A consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36:959-969
19. Fromm RE Jr: Cardiac troponins in the intensive care unit: Common causes of increased levels and interpretation. Crit Care Med 2007; 35:584-588
20. Fuchs I, Frossard M, Spiel A, et al: Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS. J Thromb Haemost 2006; 4:2547-2552
21. Frossard M, Fuchs I, Leitner JM, et al: Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 2004; 110:1392-1397
22. Jilma-Stohlawetz P, Hergovich N, Homoncik M, et al: Impaired platelet function among platelet donors. Thromb Haemost 2001; 86: 880-886
23. Spiel AO, Mayr FB, Ladani N, et al: The aptamer ARC1779 is a potent and specific inhibitor of von Willebrand Factor mediated ex vivo platelet function in acute myocardial infarction. Platelets 2009; 20:334-340
24. Gouya G, Jilma B, Niel M, et al: Cross validation of aspirin effect in healthy individuals by Impact-R and PFA-100: A double blind randomized placebo controlled trial. Platelets 2009; 20:171-176
25. Siller-Matula JM, Gouya G, Wolzt M, et al: Cross validation of the Multiple Electrode Aggregometry. A prospective trial in healthy volunteers. Thromb Haemost 2009; 102:397-403
26. Jilma B: Platelet function analyzer (PFA-100): A tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med 2001; 138:152-163
27. Macchi L, Christiaens L, Brabant S, et al: Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T(GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms. J Am Coll Cardiol 2003; 42:1115-1119
28. Reiter RA, Mayr F, Blazicek H, et al: Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. Blood 2003; 102:4594-4599
29. Crescente M, Di Castelnuovo A, Iacoviello L, et al: Response variability to aspirin as assessed by the Platelet Function Analyzer (PFA)-100. A systematic review. Thromb Haemost 2008; 99:14-26
30. Harrison P, Mackie I, Mathur A, et al: Platelet hyper-function in acute coronary syndromes. Blood Coagul Fibrinolysis 2005; 16:557-562
31. Maree AO, Curtin RJ, Dooley M, et al: Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol 2005; 46:1258-1263
32. Brambilla M, Parolari A, Camera M, et al: Effect of two doses of aspirin on thromboxane biosynthesis and platelet function in patients undergoing coronary surgery. Thromb Haemost 2010; 103:516-524
33. Bach J, Kammerer I, Isgro F, et al: The impact of intravenous aspirin administration on platelet aspirin resistance after on-pump coronary artery bypass surgery. Platelets 2009; 20:150-157
34. Leclerc JR: Platelet glycoprotein IIb/IIIa antagonists: Lessons learned from clinical trials and future directions. Crit Care Med 2002; 30:S332-S340
35. Vlaar PJ, Svilaas T, Damman K, et al: Impact of pretreatment with clopidogrel on initial patency and outcome in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: A systematic review. Circulation 2008; 118:1828-1836
36. Campo G, Valgimigli M, Gemmati D, et al: Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: Insights into the STRATEGY Study. J Am Coll Cardiol 2006; 48:2178-2185
37. Christie DJ, Kottke-Marchant K, Gorman RT: Hypersensitivity of platelets to adenosine diphosphate in patients with stable cardiovascular disease predicts major adverse events despite antiplatelet therapy. Platelets 2008; 19:104-110
38. Gori AM, Marcucci R, Paniccia R, et al: Thrombotic events in high risk patients are predicted by evaluating different pathways of platelet function. Thromb Haemost 2008; 100:1136-1145
39. Marcucci R, Paniccia R, Antonucci E, et al: Residual platelet reactivity is an independent predictor of myocardial injury in acute myocardial infarction patients on antiaggregant therapy. Thromb Haemost 2007; 98:844-851
40. Reny JL, De Moerloose P, Dauzat M, et al: Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: A systematic review and metaanalysis. J Thromb Haemost 2008; 6:444-450
41. Spiel AO, Frossard M, Mayr FB, et al: Pronounced platelet hyperfunction in patients with cardiac arrest achieving restoration of spontaneous circulation. Crit Care Med 2009; 37:975-979